A Breakthrough in Treatment for Dementia-Related Psychosis: A Review of Current and Future Managed Care Strategies

A Breakthrough in Treatment for Dementia-Related Psychosis: A Review of Current and Future Managed Care Strategies

Faculty Presenters

Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers University

Clinical Psychiatric Pharmacist
Monmouth Medical Center, RWJBarnabas Health
Long Branch, New Jersey

Alan D. Pannier, PharmD, MBA
Head of Clinical Services
SmithRx
Lehi, Utah
 
Program Description
Older adult patients with dementia-associated psychosis may experience delusions and hallucinations and exhibit agitation or aggression towards others. Current guideline recommendations for care of patients with dementia-related psychosis gives preference to nonpharmaceutical interventions, with antipsychotics reserved for use with patients experiencing severe symptoms to reduce risk of harm to themselves or others. Inappropriate use of antipsychotics for patients with dementia-related psychosis conveys safety and administration risks for older adults, which can increase direct costs to both patients and the healthcare system. Managed care professionals need to be up-to-date with clinical data associated with current and emerging therapies and should review management strategies regularly. This activity will also review the impact of dementia-related psychosis on patients and caregivers.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 27, 2021
Expiration date: April 27, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Explain the clinical presentation of dementia and the high rate of psychosis in this population as well as its effect on patients and caregivers
• Compare existing off-label use of first- and second-generation antipsychotic medications for dementia-related psychosis, including their risks and benefits
• Analyze the clinical trials for the new class of drug therapy for dementia-related psychosis
• Optimize the role of managed care professionals in developing an evidence-based access strategy that integrates a new class of drugs for dementia-related psychosis treatment

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-167-H01-P. The activity is available for CE credit through April 27, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Megan Maroney, PharmD, BCPP, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: CPNP Foundation Defining the Future research grant
• Consultant: Novus Medical Education
• Speakers Bureau: Otsuka Excel

Alan D. Pannier, PharmD, MBA, has no relevant financial relationships with commercial interests to disclose.


Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms